Russian Drug in American Market
Products of Russian Biotechnological Company Institute of Human Stem Cells (IHSC) will be marketed in the US and Canada Pharma markets. IHSC developed a genetically engineered drug Neovasculgen, intended for treatment of lower limb ischemia. The drug stimulates therapeutic angiogenesis, increases the number of permeable capillaries in ischemic tissues, improves blood supply, thus decreasing the rate of amputations and death rate.
An agreement on promotion of the drug and organization of contract manufacture in US has already been signed between IHSC and the American partners.
It is of note, that the above drug has been included into the VED list in 2016. Overall US market of drugs for lower limb ischemia is estimated at USD 12 bln.